Inside the journey: A qualitative study of intravenous ketamine therapy for treatment-resistant depression
Journal of Affective Disorders Reports April 28, 2025 Jason Perepelkin, Polixeni Hantjidis, Kirsten Robison et al. 3 citations
People with treatment-resistant depression who received intravenous ketamine at a clinic in Saskatchewan, Canada, reported significant improvements in mood, outlook, and daily functioning, along with psychological relief and altered perceptions during treatment. Barriers included high cost, limited accessibility, and stigma. The clinic environment and psychosocial factors also influenced outcomes. Despite financial burdens, many experienced meaningful benefits, including reduced suicidality. The findings underscore the need for supportive care settings, better access, and further research on individual predictors of response and cost-effectiveness.